Gregory Gorgas - President & Chief Executive Officer
Gregory D. Gorgas has served as our President, Chief Executive Officer and on our board of directors since April 2017. He holds more than three decades of successful drug development and commercialization experience in pharmaceutical and biotech companies. His accomplishments include more than a dozen product launches, four of which were first-in-class. Before leading Artelo, Mr. Gorgas served as Senior Vice President, Commercial and corporate officer at Mast Therapeutics, a publicly held biotechnology company, where he had commercial leadership accountability and business development responsibilities for the hematology, oncology and cardiovascular programs. Prior to that, Mr. Gorgas worked at Biogen, a publicly held biotechnology company, as Senior Director, Global Marketing with responsibility for the strategic vision and operational commercialization of the company’s worldwide cancer business. Previously he held leadership positions of increasing responsibility with IDEC Pharmaceuticals, Chiron, Cetus and Upjohn, all publicly held companies. Mr. Gorgas earned a BA in economics from California State University, Northridge and, from the University of Phoenix, an MBA.
Steven D. Reich, MD - Chief Medical Officer
Steven D. Reich, MD has served as our Chief Medical Officer since April 2018. Dr. Reich brought to Artelo over four decades of drug research experience, both as an academically based investigator for Phase I-III trials and as a senior leader in the biopharma industry where he designed and managed Phase I-IV trials. He has directed studies with sites in North America, Europe, and Asia. Dr. Reich’s managerial experience includes directing multinational medical research groups within pharmaceutical and biotechnology companies and at a contract research organization. He headed the clinical research programs which led to five US, one Canadian, and two European drug approvals, and he was a team member for multiple other international approvals, primarily anti-cancer drugs. Dr. Reich received his MD degree at the New Jersey College of Medicine and Dentistry and a diplomate certification from the American Board of Internal Medicine, with a sub-specialty of Medical Oncology. Dr. Reich was a clinical fellow at the Baltimore Cancer Research Center NCI, NIH, Baltimore, MD.
Andy Yates, PhD - Senior Vice President, Chief Scientific Officer
Dr. Andy Yates has served as our Chief Scientific Officer since January 2021. Dr. Yates has more than 15 years experience in the pharmaceutical industry including 10 years as an executive at AstraZeneca. He held key roles within the medical affairs, commercial, business development and strategy functions for AstraZeneca’s in-line and development portfolio. Dr Yates has been extensively involved in the life-cycle management of key multi-billion dollar products leading to the funding and initiation of significant development programmes. Whilst in business development he led evaluations and transactions that resulted in multiple collaborative agreements with academia, biotechnology and peer pharma. Dr. Yates is a UK registered pharmacist who received his PhD in cannabinoid medicinal chemistry from the University of Nottingham.
Jason Baybutt - Senior Vice President, Finance
Jason Baybutt has been providing fractional CFO and accounting services to Artelo through his firm Pubco Reporting Solutions, Inc. since September 2014. Mr. Baybutt has over 15 years of experience providing C-level consulting and capital market advisory services with both private and public companies located in North America, Europe and Asia. In addition to financial, operational, and strategic advisory experience, his expertise includes the financial complexities associated with derivatives, reverse mergers, business combinations and acquisitions. Mr. Baybutt received his finance and accounting training at Mount Royal College in Calgary, Alberta, Canada.
Saoirse Elizabeth O’Sullivan, PhD - Vice President, Translational Sciences
Prof. Saoirse Elizabeth O’Sullivan joined Artelo in October 2021 as Vice President, Translational Sciences, after having served several years as a scientific advisor to the Company. Dr. O’Sullivan received her doctorate from Trinity College Dublin in 2001 and moved to the University of Nottingham in 2002 as a Research fellow where she began researching cannabinoid pharmacology. She was made Lecturer in 2007, Associate Professor in 2011, and Professor in 2019. She has over 26 original research articles, 6 reviews and 3 books chapters on the topic of cannabinoid pharmacology, with specific interests on the cardiovascular and gastrointestinal effects of cannabinoids and therapeutic potential of cannabis-based medicines. Her research methodologies span from cellular and animal models to human healthy volunteer studies and early phase clinical trials. In 2016 she was named the International Cannabinoid Research Society Young Investigator of the Year.